These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23964615)

  • 1. Health plan utilization and costs of specialty drugs within 4 chronic conditions.
    Gleason PP; Alexander GC; Starner CI; Ritter ST; Van Houten HK; Gunderson BW; Shah ND
    J Manag Care Pharm; 2013 Sep; 19(7):542-8. PubMed ID: 23964615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.
    Kunze AM; Gunderson BW; Gleason PP; Heaton AH; Johnson SV
    J Manag Care Pharm; 2007; 13(9):799-806. PubMed ID: 18062731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization and Costs of Compounded Medications for Commercially Insured Patients, 2012-2013.
    McPherson T; Fontane P; Iyengar R; Henderson R
    J Manag Care Spec Pharm; 2016 Feb; 22(2):172-81. PubMed ID: 27015256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
    Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
    J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical Costs and Health Care Utilization Among Self-Insured Members with Carve-In Versus Carve-Out Pharmacy Benefits.
    Smith JJ; Qiu Y; Lam SV; Lockwood CM; Pegus C; Gleason PP
    J Manag Care Spec Pharm; 2020 Jun; 26(6):766-774. PubMed ID: 32154745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
    Prescott JD; Factor S; Pill M; Levi GW
    J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Specialty Medication Use for Common Chronic Inflammatory Diseases Among Health Exchange and Other Commercially Insured Members.
    Chen X; Gautam S; Ruggieri A; Richards T; Devries A; Sylwestrzak G
    J Manag Care Spec Pharm; 2018 Jan; 24(1):12-19. PubMed ID: 29290173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps.
    Yeung K; Barthold D; Dusetzina SB; Basu A
    N Engl J Med; 2020 Aug; 383(6):558-566. PubMed ID: 32757524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study.
    Khilfeh I; Guyette E; Watkins J; Danielson D; Gross D; Yeung K
    J Manag Care Spec Pharm; 2019 Apr; 25(4):461-467. PubMed ID: 30917076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases.
    Bhattacharya R; Herren K; Poonawalla I; Bunniran S; Bloomfield A; Schwab P
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1246-1256. PubMed ID: 32996385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans.
    Johnsrud M; Lawson KA; Shepherd MD
    J Manag Care Pharm; 2007 Mar; 13(2):122-34. PubMed ID: 17330973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Community pharmacy and mail order cost and utilization for 90-day maintenance medication prescriptions.
    Khandelwal N; Duncan I; Rubinstein E; Ahmed T; Pegus C
    J Manag Care Pharm; 2012 Apr; 18(3):247-55. PubMed ID: 22468733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
    Cecil WT; Barnes J; Shea T; Coulter SL
    J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
    Tungol A; Starner CI; Gunderson BW; Schafer JA; Qiu Y; Gleason PP
    J Manag Care Pharm; 2012; 18(9):690-700. PubMed ID: 23206212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults.
    Pauly NJ; Brown JD
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1162-70. PubMed ID: 26679965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of a Novel Cost-Saving Pharmacy Program on Pregabalin Use and Health Care Costs.
    Martin C; Odell K; Cappelleri JC; Bancroft T; Halpern R; Sadosky A
    J Manag Care Spec Pharm; 2016 Feb; 22(2):132-44. PubMed ID: 27015252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
    Yokoyama K; Yang W; Preblick R; Frech-Tamas F
    J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.